Specifically, patients were more likely to achieve a higher RCB classification when they were negative for UGCG and TNFRSF21, but positive for BTG2 and MYB, with no lymph node metastasis. The gene discussed is BTG2; the disease is metastatic malignant neoplasm in the lymph nodes.